Comparison of resistance against erythromycin and moxifloxacin, presence of binary toxin gene and PCR ribotypes in Clostridium difficile isolates from 1990 and 2008.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
C IlchmannH Rohde

Abstract

Worldwide increasing rates of Clostridium difficile infections (CDI) with severe courses and outbreaks have been reported. This change in CDI epidemiology has on one hand been related to the spread of specific PCR ribotypes (e.g. 027) and on the other hand to increased prevalence of resistant C. difficile strains. This single-centre retrospective analysis characterized resistance against erythromycin and moxifloxacin, presence of binary toxin gene and ribotypes in 73 C. difficile isolates from 2008 in comparison with 23 isolates from 1990. In 1990, five different PCR ribotypes including 027 were identified. Resistance against erythromycin was detected in 3 of 23 (13%), while 20 of 23 (87%) from all isolates were susceptible to both erythromycin and moxifloxacin. In contrast, in 2008 a significantly increased prevalence of resistant C. difficile strains was observed, with 40 of 73 (54.8%) isolates being resistant against both antibiotics. Resistant C. difficile strains were mainly assigned to PCR ribotype 001. No isolates belonging to PCR ribotype 027 were identified. Our data provide evidence that the increase of resistant C. difficile strains belonging to PCR ribotype 001 rather than the spread of C. difficile PCR ribotype 027...Continue Reading

References

Feb 27, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert GaynesFred C Tenover
Dec 3, 2005·The New England Journal of Medicine·L Clifford McDonaldDale N Gerding
Sep 13, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E J KuijperUNKNOWN European Centre for Disease Prevention and Control
Jul 11, 2007·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Warren N FawleyMark H Wilcox
Sep 14, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F BarbutUNKNOWN European Study Group on Clostridium difficile (ESGCD)
Apr 18, 2008·Journal of Clinical Microbiology·Maja RupnikFrédéric Barbut
Jul 18, 2009·International Journal of Antimicrobial Agents·John E Coia
Jun 17, 2009·Nature Reviews. Microbiology·Maja RupnikDale N Gerding
Nov 28, 2009·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·M ArvandG Bettge-Weller

❮ Previous
Next ❯

Citations

Aug 6, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mar Sánchez-SomolinosEmilio Bouza
Mar 26, 2013·International Journal of Medical Microbiology : IJMM·Irene WeberAna Mena
Nov 8, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Anna K BarkerNasia Safdar
Aug 10, 2021·Infection Prevention in Practice·Vanda Marujo, Mardjan Arvand

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

© 2021 Meta ULC. All rights reserved